Abstract
Oxidative stress has been implicated in the pathogenesis of a number of diseases including Alzheimer’s disease (AD). The oxidative stress hypothesis of AD pathogenesis, in part, is based on β-amyloid peptide (Aβ)-induced oxidative stress in both in vitro and in vivo studies. Oxidative modification of the protein may induce structural changes in a protein that might lead to its functional impairment. A number of oxidatively modified brain proteins were identified using redox proteomics in AD, mild cognitive impairment (MCI) and Aβ models of AD, which support a role of Aβ in the alteration of a number of biochemical and cellular processes such as energy metabolism, protein degradation, synaptic function, neuritic growth, neurotransmission, cellular defense system, long term potentiation involved in formation of memory, etc. All the redox proteomics-identified brain proteins fit well with the appearance of the three histopathological hallmarks of AD, i.e., synapse loss, amyloid plaque formation and neurofibrillary tangle formation and suggest a direct or indirect association of the identified proteins with the pathological and/or biochemical alterations in AD. Further, Aβ models of AD strongly support the notion that oxidative stress induced by Aβ may be a driving force in AD pathogenesis. Studies conducted on arguably the earliest stage of AD, MCI, may elucidate the mechanism(s) leading to AD pathogenesis by identifying early markers of the disease, and to develop therapeutic strategies to slow or prevent the progression of AD. In this review, we summarized our findings of redox proteomics identified oxidatively modified proteins in AD, MCI and AD models.
Similar content being viewed by others
References
Abdul HM, Calabrese V, Calvani M, Butterfield DA (2006) Acetyl-l-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1–42-mediated oxidative stress and neurotoxicity: implications for Alzheimer’s disease. J Neurosci Res 84:398–408. doi:10.1002/jnr.20877
Aksenova M, Butterfield DA, Zhang SX, Underwood M, Geddes JW (2002) Increased protein oxidation and decreased creatine kinase BB expression and activity after spinal cord contusion injury. J Neurotrauma 19:491–502. doi:10.1089/08977150252932433
Anantharaman M, Tangpong J, Keller JN, Murphy MP, Markesbery WR, Kiningham KK, St Clair DK (2006) Beta-amyloid mediated nitration of manganese superoxide dismutase: implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double knock-in mouse model of Alzheimer’s disease. Am J Pathol 168:1608–1618. doi:10.2353/ajpath.2006.051223
Ansari MA, Joshi G, Huang Q, Opii WO, Abdul HM, Sultana R, Butterfield DA (2006) In vivo administration of D609 leads to protection of subsequently isolated gerbil brain mitochondria subjected to in vitro oxidative stress induced by amyloid beta-peptide and other oxidative stressors: relevance to Alzheimer’s disease and other oxidative stress-related neurodegenerative disorders. Free Radic Biol Med 41:1694–1703. doi:10.1016/j.freeradbiomed.2006.09.002
Bader Lange ML, Cenini G, Piroddi M, Abdul HM, Sultana R, Galli F, Memo M, Butterfield DA (2008) Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease. Neurobiol Dis 29:456–464
Beckman JS (1996) Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol 9:836–844. doi:10.1021/tx9501445
Biroccio A, Del Boccio P, Panella M, Bernardini S, Di Ilio C, Gambi D, Stanzione P, Sacchetta P, Bernardi G, Martorana A, Federici G, Stefani A, Urbani A (2006) Differential post-translational modifications of transthyretin in Alzheimer’s disease: a study of the cerebral spinal fluid. Proteomics 6:2305–2313. doi:10.1002/pmic.200500285
Boyd-Kimball D, Castegna A, Sultana R, Poon HF, Petroze R, Lynn BC, Klein JB, Butterfield DA (2005) Proteomic identification of proteins oxidized by Abeta(1–42) in synaptosomes: implications for Alzheimer’s disease. Brain Res 1044:206–215. doi:10.1016/j.brainres.2005.02.086
Boyd-Kimball D, Poon HF, Lynn BC, Cai J, Pierce WM Jr, Klein JB, Ferguson J, Link CD, Butterfield DA (2006) Proteomic identification of proteins specifically oxidized in Caenorhabditis elegans expressing human Abeta(1–42): implications for Alzheimer’s disease. Neurobiol Aging 27:1239–1249. doi:10.1016/j.neurobiolaging.2005.07.001
Boyd-Kimball D, Sultana R, Mohmmad-Abdul H, Butterfield DA (2005) Neurotoxicity and oxidative stress in D1M-substituted Alzheimer’s A beta(1–42): relevance to N-terminal methionine chemistry in small model peptides. Peptides 26:665–673. doi:10.1016/j.peptides.2004.11.001
Boyd-Kimball D, Sultana R, Poon HF, Lynn BC, Casamenti F, Pepeu G, Klein JB, Butterfield DA (2005) Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1–42) into rat brain: implications for Alzheimer’s disease. Neuroscience 132:313–324. doi:10.1016/j.neuroscience.2004.12.022
Boyd-Kimball D, Sultana R, Poon HF, Mohmmad-Abdul H, Lynn BC, Klein JB, Butterfield DA (2005) Gamma-glutamylcysteine ethyl ester protection of proteins from Abeta(1–42)-mediated oxidative stress in neuronal cell culture: a proteomics approach. J Neurosci Res 79:707–713. doi:10.1002/jnr.20393
Brunelle P, Rauk A (2002) The radical model of Alzheimer’s disease: specific recognition of Gly29 and Gly33 by Met35 in a beta-sheet model of Abeta: an ONIOM study. J Alzheimers Dis 4:283–289
Butterfield DA (2002) Amyloid beta-peptide (1–42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer’s disease brain. A review. Free Radic Res 36:1307–1313. doi:10.1080/1071576021000049890
Butterfield DA (1997) beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer’s disease. Chem Res Toxicol 10:495–506. doi:10.1021/tx960130e
Butterfield DA, Abdul HM, Newman S, Reed T (2006) Redox proteomics in some age-related neurodegenerative disorders or models thereof. NeuroRx 3:344–357. doi:10.1016/j.nurx.2006.05.003
Butterfield DA, Boyd-Kimball D (2004) Amyloid beta-peptide(1–42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol 14:426–432
Butterfield DA, Boyd-Kimball D (2005) The critical role of methionine 35 in Alzheimer’s amyloid beta-peptide (1–42)-induced oxidative stress and neurotoxicity. Biochim Biophys Acta 1703:149–156
Butterfield DA, Boyd-Kimball D, Castegna A (2003) Proteomics in Alzheimer’s disease: insights into potential mechanisms of neurodegeneration. J Neurochem 86:1313–1327. doi:10.1046/j.1471-4159.2003.01948.x
Butterfield DA, Castegna A, Lauderback CM, Drake J (2002) Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death. Neurobiol Aging 23:655–664. doi:10.1016/S0197-4580(01)00340-2
Butterfield DA, Drake J, Pocernich C, Castegna A (2001) Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid beta-peptide. Trends Mol Med 7:548–554. doi:10.1016/S1471-4914(01)02173-6
Butterfield DA, Gnjec A, Poon HF, Castegna A, Pierce WM, Klein JB, Martins RN (2006) Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer’s disease: an initial assessment. J Alzheimers Dis 10:391–397
Butterfield DA, Hensley K, Cole P, Subramaniam R, Aksenov M, Aksenova M, Bummer PM, Haley BE, Carney JM (1997) Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer’s disease. J Neurochem 68:2451–2457
Butterfield DA, Kanski J (2001) Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech Ageing Dev 122:945–962. doi:10.1016/S0047-6374(01)00249-4
Butterfield DA, Lauderback CM (2002) Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 32:1050–1060. doi:10.1016/S0891-5849(02)00794-3
Butterfield DA, Mohmmad-Abdul H, Opii W, Newman SF, Joshi G, Ansari MA, Sultana R (2006) Role of Pin1 in Alzheimer’s disease. J Neurochem 98:1699–1706. doi:10.1111/j.1471-4159.2006.03995.x
Butterfield DA, Poon HF, St Clair D, Keller JN, Pierce WM, Klein JB, Markesbery WR (2006) Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer’s disease. Neurobiol Dis 22:223–232. doi:10.1016/j.nbd.2005.11.002
Butterfield DA, Reed T, Newman SF, Sultana R (2007) Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer’s disease and mild cognitive impairment. Free Radic Biol Med 43:658–677. doi:10.1016/j.freeradbiomed.2007.05.037
Butterfield DA, Reed T, Perluigi M, De Marco C, Coccia R, Cini C, Sultana R (2006) Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett 397:170–173. doi:10.1016/j.neulet.2005.12.017
Butterfield DA, Stadtman ER (1997) Protein Oxidation processes in aging brain. Adv Cell Aging Gerontol 2:161–191. doi:10.1016/S1566-3124(08)60057-7
Carney JM, Starke-Reed PE, Oliver CN, Landum RW, Cheng MS, Wu JF, Floyd RA (1991) Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl-alpha-phenylnitrone. Proc Natl Acad Sci USA 88:3633–3636. doi:10.1073/pnas.88.9.3633
Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 33:562–571. doi:10.1016/S0891-5849(02)00914-0
Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82:1524–1532. doi:10.1046/j.1471-4159.2002.01103.x
Castegna A, Lauderback CM, Mohmmad-Abdul H, Butterfield DA (2004) Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer’s disease. Brain Res 1004:193–197. doi:10.1016/j.brainres.2004.01.036
Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA (2003) Proteomic identification of nitrated proteins in Alzheimer’s disease brain. J Neurochem 85:1394–1401. doi:10.1046/j.1471-4159.2003.01786.x
Cenini G, Sultana R, Memo M, Butterfield DA (2008) Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer’s disease. J Cell Mol Med 12:987–994. doi:10.1111/j.1582-4934.2008.00163.x
Chang RC, Wong AK, Ng HK, Hugon J (2002) Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer’s disease. NeuroReport 13:2429–2432. doi:10.1097/00001756-200212200-00011
Chertkow H, Bergman H, Schipper HM, Gauthier S, Bouchard R, Fontaine S, Clarfield AM (2001) Assessment of suspected dementia. Can J Neurol Sci 28(Suppl 1):S28–S41
Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, Li L (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson’s and Alzheimer’s diseases. J Biol Chem 279:13256–13264. doi:10.1074/jbc.M314124200
Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, Li L (2005) Oxidative modifications and aggregation of Cu, Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem 280:11648–11655. doi:10.1074/jbc.M414327200
Clementi ME, Pezzotti M, Orsini F, Sampaolese B, Mezzogori D, Grassi C, Giardina B, Misiti F (2006) Alzheimer’s amyloid beta-peptide (1–42) induces cell death in human neuroblastoma via bax/bcl-2 ratio increase: an intriguing role for methionine 35. Biochem Biophys Res Commun 342:206–213. doi:10.1016/j.bbrc.2006.01.137
Coleman PD, Flood DG (1987) Neuron numbers and dendritic extent in normal aging and Alzheimer’s disease. Neurobiol Aging 8:521–545. doi:10.1016/0197-4580(87)90127-8
Cotman CW, Head E, Muggenburg BA, Zicker S, Milgram NW (2002) Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction. Neurobiol Aging 23:809–818. doi:10.1016/S0197-4580(02)00073-8
Coyle JT, Price DL, DeLong MR (1983) Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 219:1184–1190. doi:10.1126/science.6338589
Crouch PJ, Barnham KJ, Duce JA, Blake RE, Masters CL, Trounce IA (2006) Copper-dependent inhibition of cytochrome c oxidase by Abeta(1–42) requires reduced methionine at residue 35 of the Abeta peptide. J Neurochem 99:226–236. doi:10.1111/j.1471-4159.2006.04050.x
Cummings BJ, Head E, Ruehl W, Milgram NW, Cotman CW (1996) The canine as an animal model of human aging and dementia. Neurobiol Aging 17:259–268. doi:10.1016/0197-4580(95)02060-8
Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc Natl Acad Sci USA 101:2070–2075. doi:10.1073/pnas.0305799101
Dalle-Donne I, Scaloni A, Butterfield DA (2006) Redox proteomics: from protein modifications to cellular dysfunction and diseases. Wiley, Hoboken
Dalle-Donne I, Scaloni A, Giustarini D, Cavarra E, Tell G, Lungarella G, Colombo R, Rossi R, Milzani A (2005) Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics. Mass Spectrom Rev 24:55–99. doi:10.1002/mas.20006
Davies MJ, Fu S, Wang H, Dean RT (1999) Stable markers of oxidant damage to proteins and their application in the study of human disease. Free Radic Biol Med 27:1151–1163. doi:10.1016/S0891-5849(99)00206-3
Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 280:17294–17300. doi:10.1074/jbc.M500997200
Ding Q, Markesbery WR, Cecarini V, Keller JN (2006) Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer’s disease. Neurochem Res 31:705–710. doi:10.1007/s11064-006-9071-5
Ding Q, Markesbery WR, Chen Q, Li F, Keller JN (2005) Ribosome dysfunction is an early event in Alzheimer’s disease. J Neurosci 25:9171–9175. doi:10.1523/JNEUROSCI.3040-05.2005
Drake J, Link CD, Butterfield DA (2003) Oxidative stress precedes fibrillar deposition of Alzheimer’s disease amyloid beta-peptide (1–42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging 24:415–420. doi:10.1016/S0197-4580(02)00225-7
Dyrks T, Dyrks E, Hartmann T, Masters C, Beyreuther K (1992) Amyloidogenicity of beta A4 and beta A4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J Biol Chem 267:18210–18217
Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11:81–128. doi:10.1016/0891-5849(91)90192-6
Farooqui AA, Horrocks LA (2006) Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly. Neuroscientist 12:245–260. doi:10.1177/1073858405285923
Ferl RJ (1996) 14-3-3 proteins and signal transduction. Annu Rev Plant Physiol Plant Mol Biol 47:49–73. doi:10.1146/annurev.arplant.47.1.49
Fisher A (2008) Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer’s disease. Neurotherapeutics 5:433–442. doi:10.1016/j.nurt.2008.05.002
Fisher A (1999) Muscarinic receptor agonists in Alzheimer’s disease: more than just symptomatic treatment? CNS Drugs 123:197–214. doi:10.2165/00023210-199912030-00004
Geula C, Nagykery N, Nicholas A, Wu CK (2008) Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease. J Neuropathol Exp Neurol 67:309–318. doi:10.1097/NEN.0b013e31816a1df3
Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S, Pepeu G, Casamenti F (2002) Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis 11:257–274. doi:10.1006/nbdi.2002.0538
Gong B, Cao Z, Zheng P, Vitolo OV, Liu S, Staniszewski A, Moolman D, Zhang H, Shelanski M, Arancio O (2006) Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 126:775–788. doi:10.1016/j.cell.2006.06.046
Gothel SF, Marahiel MA (1999) Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Cell Mol Life Sci 55:423–436. doi:10.1007/s000180050299
Guidi I, Galimberti D, Lonati S, Novembrino C, Bamonti F, Tiriticco M, Fenoglio C, Venturelli E, Baron P, Bresolin N, Scarpini E (2006) Oxidative imbalance in patients with mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging 27:262–269. doi:10.1016/j.neurobiolaging.2005.01.001
Halliwell B (2006) Oxidative stress and neurodegeneration: where are we now? J Neurochem 97:1634–1658. doi:10.1111/j.1471-4159.2006.03907.x
Hamdane M, Dourlen P, Bretteville A, Sambo AV, Ferreira S, Ando K, Kerdraon O, Begard S, Geay L, Lippens G, Sergeant N, Delacourte A, Maurage CA, Galas MC, Buee L (2006) Pin1 allows for differential Tau dephosphorylation in neuronal cells. Mol Cell Neurosci 32:155–160. doi:10.1016/j.mcn.2006.03.006
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356. doi:10.1126/science.1072994
Head E, Callahan H, Muggenburg BA, Cotman CW, Milgram NW (1998) Visual-discrimination learning ability and beta-amyloid accumulation in the dog. Neurobiol Aging 19:415–425. doi:10.1016/S0197-4580(98)00084-0
Head E, Torp R (2002) Insights into Abeta and presenilin from a canine model of human brain aging. Neurobiol Dis 9:1–10. doi:10.1006/nbdi.2002.0476
Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita SP, Wu JF, Carney JM et al (1995) Brain regional correspondence between Alzheimer’s disease histopathology and biomarkers of protein oxidation. J Neurochem 65:2146–2156
Holzer M, Gartner U, Stobe A, Hartig W, Gruschka H, Bruckner MK, Arendt T (2002) Inverse association of Pin1 and tau accumulation in Alzheimer’s disease hippocampus. Acta Neuropathol 104:471–481
Ischiropoulos H, al-Mehdi AB (1995) Peroxynitrite-mediated oxidative protein modifications. FEBS Lett 364:279–282. doi:10.1016/0014-5793(95)00307-U
Joshi G, Perluigi M, Sultana R, Agrippino R, Calabrese V, Butterfield DA (2006) In vivo protection of synaptosomes by ferulic acid ethyl ester (FAEE) from oxidative stress mediated by 2,2-azobis(2-amidino-propane)dihydrochloride (AAPH) or Fe(2+)/H(2)O(2): insight into mechanisms of neuroprotection and relevance to oxidative stress-related neurodegenerative disorders. Neurochem Int 48:318–327. doi:10.1016/j.neuint.2005.11.006
Joshi G, Sultana R, Perluigi M, Allan Butterfield D (2005) In vivo protection of synaptosomes from oxidative stress mediated by Fe2+/H2O2 or 2, 2-azobis-(2-amidinopropane) dihydrochloride by the glutathione mimetic tricyclodecan-9-yl-xanthogenate. Free Radic Biol Med 38:1023–1031. doi:10.1016/j.freeradbiomed.2004.12.027
Kanski J, Aksenova M, Schoneich C, Butterfield DA (2002) Substitution of isoleucine-31 by helical-breaking proline abolishes oxidative stress and neurotoxic properties of Alzheimer’s amyloid beta-peptide. Free Radic Biol Med 32:1205–1211. doi:10.1016/S0891-5849(02)00821-3
Kanski J, Varadarajan S, Aksenova M, Butterfield DA (2002) Role of glycine-33 and methionine-35 in Alzheimer’s amyloid beta-peptide 1–42-associated oxidative stress and neurotoxicity. Biochim Biophys Acta 1586:190–198
Keller JN, Hanni KB, Markesbery WR (2000) Impaired proteasome function in Alzheimer’s disease. J Neurochem 75:436–439. doi:10.1046/j.1471-4159.2000.0750436.x
Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR (2005) Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64:1152–1156
Korolainen MA, Goldsteins G, Alafuzoff I, Koistinaho J, Pirttila T (2002) Proteomic analysis of protein oxidation in Alzheimer’s disease brain. Electrophoresis 23:3428–3433. doi:10.1002/1522-2683(200210)23:19<3428::AID-ELPS3428>3.0.CO;2-5
Korolainen MA, Goldsteins G, Nyman TA, Alafuzoff I, Koistinaho J, Pirttila T (2006) Oxidative modification of proteins in the frontal cortex of Alzheimer’s disease brain. Neurobiol Aging 27:42–53. doi:10.1016/j.neurobiolaging.2004.11.010
Lafon-Cazal M, Fagni L, Guiraud MJ, Mary S, Lerner-Natoli M, Pin JP, Shigemoto R, Bockaert J (1999) mGluR7-like metabotropic glutamate receptors inhibit NMDA-mediated excitotoxicity in cultured mouse cerebellar granule neurons. Eur J NeuroSci 11:663–672. doi:10.1046/j.1460-9568.1999.00475.x
Lahiri DK, Ge YW, Maloney B, Wavrant-De Vrieze F, Hardy J (2005) Characterization of two APP gene promoter polymorphisms that appear to influence risk of late-onset Alzheimer’s disease. Neurobiol Aging 26:1329–1341. doi:10.1016/j.neurobiolaging.2004.11.005
Lambert JC, Mann DM, Harris JM, Chartier-Harlin MC, Cumming A, Coates J, Lemmon H, StClair D, Iwatsubo T, Lendon C (2001) The −48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer’s disease and an increased Abeta load in brain. J Med Genet 38:353–355. doi:10.1136/jmg.38.6.353
Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA (2001) The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer’s disease brain: the role of Abeta1–42. J Neurochem 78:413–416. doi:10.1046/j.1471-4159.2001.00451.x
Layfield R, Fergusson J, Aitken A, Lowe J, Landon M, Mayer RJ (1996) Neurofibrillary tangles of Alzheimer’s disease brains contain 14-3-3 proteins. Neurosci Lett 209:57–60. doi:10.1016/0304-3940(96)12598-2
Levine RL, Williams JA, Stadtman ER, Shacter E (1994) Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol 233:346–357. doi:10.1016/S0076-6879(94)33040-9
Levy-Lahad E, Lahad A, Wijsman EM, Bird TD, Schellenberg GD (1995) Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer’s disease. Ann Neurol 38:678–680. doi:10.1002/ana.410380420
Li X, An WL, Alafuzoff I, Soininen H, Winblad B, Pei JJ (2004) Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain. NeuroReport 15:2237–2240. doi:10.1097/00001756-200410050-00019
Ling M, Merante F, Chen HS, Duff C, Duncan AM, Robinson BH (1997) The human mitochondrial elongation factor tu (EF-Tu) gene: cDNA sequence, genomic localization, genomic structure, and identification of a pseudogene. Gene 197:325–336. doi:10.1016/S0378-1119(97)00279-5
Link CD (2006) C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer’s disease. Exp Gerontol 41:1007–1013. doi:10.1016/j.exger.2006.06.059
Link CD (1995) Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci USA 92:9368–9372. doi:10.1073/pnas.92.20.9368
Liou YC, Sun A, Ryo A, Zhou XZ, Yu ZX, Huang HK, Uchida T, Bronson R, Bing G, Li X, Hunter T, Lu KP (2003) Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 424:556–561. doi:10.1038/nature01832
Lledo PM, Zhang X, Sudhof TC, Malenka RC, Nicoll RA (1998) Postsynaptic membrane fusion and long-term potentiation. Science 279:399–403. doi:10.1126/science.279.5349.399
Lovell MA, Markesbery WR (2007) Oxidative damage in mild cognitive impairment and early Alzheimer’s disease. J Neurosci Res 85:3036–3040. doi:10.1002/jnr.21346
Lovell MA, Markesbery WR (2001) Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid. Arch Neurol 58:392–396. doi:10.1001/archneur.58.3.392
Lovell MA, Xie C, Markesbery WR (2001) Acrolein is increased in Alzheimer’s disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 22:187–194. doi:10.1016/S0197-4580(00)00235-9
Lu KP, Hanes SD, Hunter T (1996) A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 380:544–547. doi:10.1038/380544a0
Lubec G, Nonaka M, Krapfenbauer K, Gratzer M, Cairns N, Fountoulakis M (1999) Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer’s disease brain is downregulated at the mRNA and dysregulated at the protein level. J Neural Transm Suppl 57:161–177
Marin R, Ramirez CM, Gonzalez M, Gonzalez-Munoz E, Zorzano A, Camps M, Alonso R, Diaz M (2007) Voltage-dependent anion channel (VDAC) participates in amyloid beta-induced toxicity and interacts with plasma membrane estrogen receptor alpha in septal and hippocampal neurons. Mol Membr Biol 24:148–160. doi:10.1080/09687860601055559
Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP (1997) A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J Neurochem 68:255–264
Markesbery WR (1997) Oxidative stress hypothesis in Alzheimer’s disease. Free Radic Biol Med 23:134–147. doi:10.1016/S0891-5849(96)00629-6
Markesbery WR, Lovell MA (1998) Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer’s disease. Neurobiol Aging 19:33–36. doi:10.1016/S0197-4580(98)00009-8
Mattson MP, Partin J, Begley JG (1998) Amyloid beta-peptide induces apoptosis-related events in synapses and dendrites. Brain Res 807:167–176. doi:10.1016/S0006-8993(98)00763-X
Mazzola JL, Sirover MA (2001) Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer’s disease and in Huntington’s disease fibroblasts. J Neurochem 76:442–449. doi:10.1046/j.1471-4159.2001.00033.x
Meier-Ruge W, Iwangoff P, Reichlmeier K (1984) Neurochemical enzyme changes in Alzheimer’s and Pick’s disease. Arch Gerontol Geriatr 3:161–165. doi:10.1016/0167-4943(84)90007-4
Mello CF, Sultana R, Piroddi M, Cai J, Pierce WM, Klein JB, Butterfield DA (2007) Acrolein induces selective protein carbonylation in synaptosomes. Neuroscience 147:674–679. doi:10.1016/j.neuroscience.2007.04.003
Milgram NW, Head E, Zicker SC, Ikeda-Douglas CJ, Murphey H, Muggenburg B, Siwak C, Tapp D, Cotman CW (2005) Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year longitudinal study. Neurobiol Aging 26:77–90. doi:10.1016/j.neurobiolaging.2004.02.014
Milgram NW, Zicker SC, Head E, Muggenburg BA, Murphey H, Ikeda-Douglas CJ, Cotman CW (2002) Dietary enrichment counteracts age-associated cognitive dysfunction in canines. Neurobiol Aging 23:737–745. doi:10.1016/S0197-4580(02)00020-9
Mohmmad Abdul H, Butterfield DA (2005) Protection against amyloid beta-peptide (1–42)-induced loss of phospholipid asymmetry in synaptosomal membranes by tricyclodecan-9-xanthogenate (D609) and ferulic acid ethyl ester: implications for Alzheimer’s disease. Biochim Biophys Acta 1741:140–148
Mohmmad Abdul H, Sultana R, Keller JN, St Clair DK, Markesbery WR, Butterfield DA (2006) Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1–42), HO and kainic acid: implications for Alzheimer’s disease. J Neurochem 96:1322–1335. doi:10.1111/j.1471-4159.2005.03647.x
Mohmmad Abdul H, Wenk GL, Gramling M, Hauss-Wegrzyniak B, Butterfield DA (2004) APP and PS-1 mutations induce brain oxidative stress independent of dietary cholesterol: implications for Alzheimer’s disease. Neurosci Lett 368:148–150. doi:10.1016/j.neulet.2004.06.077
Montine TJ, Neely MD, Quinn JF, Beal MF, Markesbery WR, Roberts LJ, Morrow JD (2002) Lipid peroxidation in aging brain and Alzheimer’s disease. Free Radic Biol Med 33:620–626. doi:10.1016/S0891-5849(02)00807-9
Morris JC (2005) Mild cognitive impairment and preclinical Alzheimer’s disease. Geriatrics Suppl:9–14
Munch G, Thome J, Foley P, Schinzel R, Riederer P (1997) Advanced glycation endproducts in ageing and Alzheimer’s disease. Brain Res Brain Res Rev 23:134–143. doi:10.1016/S0165-0173(96)00016-1
Murphy MP, Beckett TL, Ding Q, Patel E, Markesbery WR, St Clair DK, LeVine H 3rd, Keller JN (2007) Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol Dis 27:301–311. doi:10.1016/j.nbd.2007.06.002
Murray IV, Sindoni ME, Axelsen PH (2005) Promotion of oxidative lipid membrane damage by amyloid beta proteins. Biochemistry 44:12606–12613. doi:10.1021/bi050926p
Negash S, Petersen LE, Geda YE, Knopman DS, Boeve BF, Smith GE, Ivnik RJ, Howard DV, Howard JH Jr, Petersen RC (2007) Effects of ApoE genotype and mild cognitive impairment on implicit learning. Neurobiol Aging 28:885–893. doi:10.1016/j.neurobiolaging.2006.04.004
Oda T, Wals P, Osterburg HH, Johnson SA, Pasinetti GM, Morgan TE, Rozovsky I, Stine WB, Snyder SW, Holzman TF et al (1995) Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1–42) and forms slowly sedimenting Abeta complexes that cause oxidative stress. Exp Neurol 136:22–31. doi:10.1006/exnr.1995.1080
Ojika K (1998). Hippocampal cholinergic neurostimulating peptide Seikagaku 70:1175–1180
Opii WO, Joshi G, Head E, Milgram NW, Muggenburg BA, Klein JB, Pierce WM, Cotman CW, Butterfield DA (2008) Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer’s disease. Neurobiol Aging 29:51–70. doi:10.1016/j.neurobiolaging.2006.09.012
Pancholi V (2001) Multifunctional alpha-enolase: its role in diseases. Cell Mol Life Sci 58:902–920. doi:10.1007/PL00000910
Parnetti L, Palumbo B, Cardinali L, Loreti F, Chionne F, Cecchetti R, Senin U (1995) Cerebrospinal fluid neuron-specific enolase in Alzheimer’s disease and vascular dementia. Neurosci Lett 183:43–45. doi:10.1016/0304-3940(94)11110-5
Pastorino L, Sun A, Lu PJ, Zhou XZ, Balastik M, Finn G, Wulf G, Lim J, Li SH, Li X, Xia W, Nicholson LK, Lu KP (2006) The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 440:528–534. doi:10.1038/nature04543
Perluigi M, Fai Poon H, Hensley K, Pierce WM, Klein JB, Calabrese V, De Marco C, Butterfield DA (2005) Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice—a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med 38:960–968. doi:10.1016/j.freeradbiomed.2004.12.021
Perluigi M, Joshi G, Sultana R, Calabrese V, De Marco C, Coccia R, Butterfield DA (2006) In vivo protection by the xanthate tricyclodecan-9-yl-xanthogenate against amyloid beta-peptide (1–42)-induced oxidative stress. Neuroscience 138:1161–1170. doi:10.1016/j.neuroscience.2005.12.004
Perluigi M, Joshi G, Sultana R, Calabrese V, De Marco C, Coccia R, Cini C, Butterfield DA (2006) In vivo protective effects of ferulic acid ethyl ester against amyloid-beta peptide 1–42-induced oxidative stress. J Neurosci Res 84:418–426. doi:10.1002/jnr.20879
Perluigi M, Sultana R, Cenini G, Di Domenico F, Memo M, Pierce WM, Coccia R, Butterfield DA (2009) Redox proteomics identification of HNE-modified brain proteins in Alzheimers disease: Role of lipid peroxidation in AD pathogenesis. Proteomics Clin Appli (Accepted)
Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, Blessed G, Fairbairn A, Tomlinson BE, Perry RH (1985) Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 48:413–421. doi:10.1136/jnnp.48.5.413
Pestova TV, Hellen CU (2000) The structure and function of initiation factors in eukaryotic protein synthesis. Cell Mol Life Sci 57:651–674. doi:10.1007/PL00000726
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303–308. doi:10.1001/archneur.56.3.303
Poon HF, Farr SA, Thongboonkerd V, Lynn BC, Banks WA, Morley JE, Klein JB, Butterfield DA (2005) Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with alpha-lipoic acid: implications for aging and age-related neurodegenerative disorders. Neurochem Int 46:159–168. doi:10.1016/j.neuint.2004.07.008
Poon HF, Shepherd HM, Reed TT, Calabrese V, Stella AM, Pennisi G, Cai J, Pierce WM, Klein JB, Butterfield DA (2006) Proteomics analysis provides insight into caloric restriction mediated oxidation and expression of brain proteins associated with age-related impaired cellular processes: Mitochondrial dysfunction, glutamate dysregulation and impaired protein synthesis. Neurobiol Aging 27:1020–1034. doi:10.1016/j.neurobiolaging.2005.05.014
Power JH, Asad S, Chataway TK, Chegini F, Manavis J, Temlett JA, Jensen PH, Blumbergs PC, Gai WP (2008) Peroxiredoxin 6 in human brain: molecular forms, cellular distribution and association with Alzheimer’s disease pathology. Acta Neuropathol 115:611–622. doi:10.1007/s00401-008-0373-3
Ralat LA, Manevich Y, Fisher AB, Colman RF (2006) Direct evidence for the formation of a complex between 1-cysteine peroxiredoxin and glutathione S-transferase pi with activity changes in both enzymes. Biochemistry 45:360–372. doi:10.1021/bi0520737
Ramakers IH, Visser PJ, Aalten P, Bekers O, Sleegers K, van Broeckhoven CL, Jolles J, Verhey FR (2008) The association between APOE genotype and memory dysfunction in subjects with mild cognitive impairment is related to age and Alzheimer pathology. Dement Geriatr Cogn Disord 26:101–108. doi:10.1159/000144072
Ramakrishnan P, Dickson DW, Davies P (2003) Pin1 colocalization with phosphorylated tau in Alzheimer’s disease and other tauopathies. Neurobiol Dis 14:251–264. doi:10.1016/S0969-9961(03)00109-8
Reed T, Perluigi M, Sultana R, Pierce WM, Klein JB, Turner DM, Coccia R, Markesbery WR, Butterfield DA (2008) Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer’s disease. Neurobiol Dis 30:107–120. doi:10.1016/j.nbd.2007.12.007
Renes J, de Vries EE, Hooiveld GJ, Krikken I, Jansen PL, Muller M (2000) Multidrug resistance protein MRP1 protects against the toxicity of the major lipid peroxidation product 4-hydroxynonenal. Biochem J 350(Pt 2):555–561. doi:10.1042/0264-6021:3500555
Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P (2003) Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer’s disease. Neurobiol Aging 24:915–919. doi:10.1016/S0197-4580(03)00031-9
Sadik G, Tanaka T, Kato K, Yamamori H, Nessa BN, Morihara T, Takeda M (2008) Phosphorylation of tau at Ser214 mediates its interaction with 14-3-3 protein: implications for the mechanism of tau aggregation. J Neurochem 108:33–43
Santoni V, Molloy M, Rabilloud T (2000) Membrane proteins and proteomics: un amour impossible? Electrophoresis 21:1054–1070. doi:10.1002/(SICI)1522-2683(20000401)21:6<1054::AID-ELPS1054>3.0.CO;2-8
Santpere G, Puig B, Ferrer I (2007) Oxidative damage of 14-3-3 zeta and gamma isoforms in Alzheimer’s disease and cerebral amyloid angiopathy. Neuroscience 146:1640–1651. doi:10.1016/j.neuroscience.2007.03.013
Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766
Shimizu H, Banno Y, Sumi N, Naganawa T, Kitajima Y, Nozawa Y (1999) Activation of p38 mitogen-activated protein kinase and caspases in UVB-induced apoptosis of human keratinocyte HaCaT cells. J Invest Dermatol 112:769–774. doi:10.1046/j.1523-1747.1999.00582.x
Sly WS, Hu PY (1995) Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 64:375–401. doi:10.1146/annurev.bi.64.070195.002111
Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G (1997) Widespread peroxynitrite-mediated damage in Alzheimer’s disease. J Neurosci 17:2653–2657
Smith MA, Richey PL, Taneda S, Kutty RK, Sayre LM, Monnier VM, Perry G (1994) Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimer’s disease. Ann N Y Acad Sci 738:447–454
Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT (2005) Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci 25:7278–7287. doi:10.1523/JNEUROSCI.1879-05.2005
Stadtman ER, Berlett BS (1997) Reactive oxygen-mediated protein oxidation in aging and disease. Chem Res Toxicol 10:485–494. doi:10.1021/tx960133r
Stenbeck G (1998) Soluble NSF-attachment proteins. Int J Biochem Cell Biol 30:573–577. doi:10.1016/S1357-2725(97)00064-2
Subramaniam R, Roediger F, Jordan B, Mattson MP, Keller JN, Waeg G, Butterfield DA (1997) The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J Neurochem 69:1161–1169
Suh YH, Checler F (2002) Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer’s disease. Pharmacol Rev 54:469–525. doi:10.1124/pr.54.3.469
Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Markesbery WR, Zhou XZ, Lu KP, Butterfield DA (2006) Oxidative modification and down-regulation of Pin1 in Alzheimer’s disease hippocampus: a redox proteomics analysis. Neurobiol Aging 27:918–925. doi:10.1016/j.neurobiolaging.2005.05.005
Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Merchant M, Markesbery WR, Butterfield DA (2006) Redox proteomics identification of oxidized proteins in Alzheimer’s disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging 27:1564–1576. doi:10.1016/j.neurobiolaging.2005.09.021
Sultana R, Butterfield DA (2004) Oxidatively modified GST and MRP1 in Alzheimer’s disease brain: implications for accumulation of reactive lipid peroxidation products. Neurochem Res 29:2215–2220. doi:10.1007/s11064-004-7028-0
Sultana R, Newman S, Mohmmad-Abdul H, Keller JN, Butterfield DA (2004) Protective effect of the xanthate, D609, on Alzheimer’s amyloid beta-peptide (1–42)-induced oxidative stress in primary neuronal cells. Free Radic Res 38:449–458. doi:10.1080/1071576042000206478
Sultana R, Newman SF, Abdul HM, Cai J, Pierce WM, Klein JB, Merchant M, Butterfield DA (2006) Protective effect of D609 against amyloid-beta1–42-induced oxidative modification of neuronal proteins: redox proteomics study. J Neurosci Res 84:409–417. doi:10.1002/jnr.20876
Sultana R, Perluigi M, Butterfield DA (2006) Redox proteomics identification of oxidatively modified proteins in Alzheimer’s disease brain and in vivo and in vitro models of AD centered around Abeta(1–42). J Chromatogr B Analyt Technol Biomed Life Sci 833:3–11. doi:10.1016/j.jchromb.2005.09.024
Sultana R, Piroddi M, Galli F, Butterfield DA (2008) Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment. Neurochem Res 33:2540–2546. doi:10.1007/s11064-008-9593-0
Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, Markesbery WR, Butterfield DA (2006) Identification of nitrated proteins in Alzheimer’s disease brain using a redox proteomics approach. Neurobiol Dis 22:76–87. doi:10.1016/j.nbd.2005.10.004
Sultana R, Ravagna A, Mohmmad-Abdul H, Calabrese V, Butterfield DA (2005) Ferulic acid ethyl ester protects neurons against amyloid beta- peptide(1–42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J Neurochem 92:749–758. doi:10.1111/j.1471-4159.2004.02899.x
Sultana R, Reed T, Perluigi M, Coccia R, Pierce WM, Butterfield DA (2007) Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study. J Cell Mol Med 11:839–851. doi:10.1111/j.1582-4934.2007.00065.x
Tamagno E, Parola M, Guglielmotto M, Santoro G, Bardini P, Marra L, Tabaton M, Danni O (2003) Multiple signaling events in amyloid beta-induced, oxidative stress-dependent neuronal apoptosis. Free Radic Biol Med 35:45–58. doi:10.1016/S0891-5849(03)00244-2
Tamagno E, Robino G, Obbili A, Bardini P, Aragno M, Parola M, Danni O (2003) H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp Neurol 180:144–155. doi:10.1016/S0014-4886(02)00059-6
Tchaikovskaya T, Fraifeld V, Urphanishvili T, Andorfer JH, Davies P, Listowsky I (2005) Glutathione S-transferase hGSTM3 and ageing-associated neurodegeneration: relationship to Alzheimer’s disease. Mech Ageing Dev 126:309–315. doi:10.1016/j.mad.2004.08.029
Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572–580. doi:10.1002/ana.410300410
Thompson J, Dahlberg AE (2004) Testing the conservation of the translational machinery over evolution in diverse environments: assaying Thermus thermophilus ribosomes and initiation factors in a coupled transcription-translation system from Escherichia coli. Nucleic Acids Res 32:5954–5961. doi:10.1093/nar/gkh925
Tremblay C, Pilote M, Phivilay A, Emond V, Bennett DA, Calon F (2007) Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis 12:377–390
Uchida K, Stadtman ER (1992) Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc Natl Acad Sci USA 89:4544–4548. doi:10.1073/pnas.89.10.4544
Viola KL, Velasco PT, Klein WL (2008) Why Alzheimer’s is a disease of memory: the attack on synapses by A beta oligomers (ADDLs). J Nutr Health Aging 12:51S–57S. doi:10.1007/BF02982587
Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, Benedek GB, Selkoe DJ, Teplow DB (1999) Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 274:25945–25952. doi:10.1074/jbc.274.36.25945
Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ (2002) Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 30:552–557. doi:10.1042/BST0300552
Watson GS, Craft S (2004) Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer’s disease. Eur J Pharmacol 490:97–113. doi:10.1016/j.ejphar.2004.02.048
Wevers A, Witter B, Moser N, Burghaus L, Banerjee C, Steinlein OK, Schutz U, de Vos RA, Steur EN, Lindstrom J, Schroder H (2000) Classical Alzheimer features and cholinergic dysfunction: towards a unifying hypothesis? Acta Neurol Scand Suppl 176:42–48. doi:10.1034/j.1600-0404.2000.00306.x
Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR (1981) Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10:122–126. doi:10.1002/ana.410100203
Williams TI, Lynn BC, Markesbery WR, Lovell MA (2006) Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer’s disease. Neurobiol Aging 27:1094–1099. doi:10.1016/j.neurobiolaging.2005.06.004
Yatin SM, Varadarajan S, Butterfield DA (2000) Vitamin E prevents Alzheimer’s amyloid beta-peptide (1–42)-induced neuronal protein oxidation and reactive oxygen species production. J Alzheimers Dis 2:123–131
Yatin SM, Varadarajan S, Link CD, Butterfield DA (1999) In vitro and in vivo oxidative stress associated with Alzheimer’s amyloid beta-peptide (1–42). Neurobiol Aging 20:325–330. doi:10.1016/S0197-4580(99)00056-1 discussion 39-42
Zarkovic K (2003) 4-hydroxynonenal and neurodegenerative diseases. Mol Aspects Med 24:293–303. doi:10.1016/S0098-2997(03)00024-4
Zhou XZ, Kops O, Werner A, Lu PJ, Shen M, Stoller G, Kullertz G, Stark M, Fischer G, Lu KP (2000) Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell 6:873–883. doi:10.1016/S1097-2765(05)00083-3
Acknowledgments
This work was supported in part by grants from NIH to D.A.B. [AG-05119; AG-10836; AG-029839].
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sultana, R., Perluigi, M. & Butterfield, D.A. Oxidatively modified proteins in Alzheimer’s disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol 118, 131–150 (2009). https://doi.org/10.1007/s00401-009-0517-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00401-009-0517-0